A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)

OBJECTIVE: To describe the rationale for a novel study design and baseline characteristics of a disease‐modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). METHODS: STEADY‐PDIII is a 36‐month, Phase 3, parallel group, placebo‐controlled study of the efficacy of isradipine 10 m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Clin Transl Neurol
Autori principali: Biglan, Kevin M., Oakes, David, Lang, Anthony E., Hauser, Robert A., Hodgeman, Karen, Greco, Brittany, Lowell, Jillian, Rockhill, Rebecca, Shoulson, Ira, Venuto, Charles, Young, Diony, Simuni, Tanya
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454402/
https://ncbi.nlm.nih.gov/pubmed/28589163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.412
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi